Obsessive–compulsive disorder
A form of psychotherapy called "cognitive behavioral therapy" (CBT) and psychotropic medications are first-line treatments for OCD. Other forms of psychotherapy, such as psychodynamic and psychoanalysis may help in managing some aspects of the disorder, but in 2007 the American Psychiatric Association (APA) noted a lack of controlled studies showing their effectiveness "in dealing with the core symptoms of OCD". The fact that many individuals do not seek treatment may be due in part to stigma associated with OCD.
Fluvoxamine
Fluvoxamine's only FDA approved indication is in the treatment of OCD, although in other countries (e.g. Australia, the UK, and Russia) it also has indications for major depressive disorder. In Japan it is currently approved to treat OCD, SAD and MDD. Fluvoxamine is indicated for children and adolescents with OCD. The drug works long-term, and retains its therapeutic efficacy for at least a year. It has also been found to possess some analgesic properties in line with other SSRIs and tricyclic antidepressants.